FBT News and Press, First Trust Amex Biotech Index Fund From 12/26/20

Recent positive developments in COVID-19 vaccines have spurred a wave of market exuberance, lifting share prices of biotech companies at the forefront of the vaccine race. COVID-19 and the urgency to find a cure have opened up opportunities, making the biotech sector a prospective spa...

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus. Firms are forging ahead with testing, treatment and vaccine research and product development. Results of even the most promising treatments, however, are not yet clear cut....

By Wvan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group, and Wendy Lam, Ph.D., Portfolio Manager and Research Analyst, Franklin Biotechnology Discovery Fund Innovation has always been a key driver for the biotechnology industry. Even in the midst of the CO...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications. ACADIA is well prepared financially and has t...

When Mr. Market succumbed to coronavirus after February 19, everything seemed to collapse in unison. In reality, some sectors fell a bit harder while others were a bit less bad, but on the whole, everybody who had money in stocks felt ill. When it comes to the snapback (or bear-market rally) ...

Question: Why are there so many ETFs? Answer: ETF providers tend to make lots of money on each ETF so they create more products to sell. The large number of ETFs has little to do with serving your best interests. We leverage our data to identify three red flags you can use to avoid the wor...

Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to start the year. This continues their impressive streak from 2019. But are the current tech valuations sustainable? In a recent mark...

By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...

Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...